ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
The polyunsaturated fatty acid and oxylipin plasma signature of aneurysmal subarachnoid haemorrhage, case-control study.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic metabolic reprogramming within 24 h predicts delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.Frontiers in neuroscience · 2026Article
- Rising burden of subarachnoid hemorrhage linked to high systolic blood pressure among young and middle-aged populations: temporal trends and global implication.Frontiers in human neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delayed cerebral ischemia (DCI) following aneurysmal subarachnoid haemorrhage (aSAH) is a complex and acute condition with limited options for early detection and effective treatments. The plasma levels of individual polyunsaturated fatty acids (PUFA) and their bioactive metabolites (oxylipins) of aSAH patients both at admission and over time remain largely unexplored, particularly concerning the development of DCI. In this study, plasma samples of aSAH patients were collected at admission and on days 4, 10, and 21 post-admission. ASAH patients who did not develop DCI were age- and sex matched to aSAH patients who did develop DCI. Control groups included patients with an unruptured aneurysm (UA) and healthy controls (HC). PUFA and oxylipin levels in plasma were measured using liquid chromatography with tandem mass spectrometry and were analysed using non-parametric univariate tests. At admission, aSAH (n = 47) patients showed elevated levels of several PUFAs, such as linoleic acid and arachidonic acid, as well as oxylipins, including 12-HETE, 20-HETE and 19,20-DiHDPA, compared to UA (n = 24) and HC (n = 13). 12-HETE was predominantly found in the S-configuration, indicating synthesis via 12(S)-lipoxygenase. PUFA and oxylipin levels dropped significantly by day four post-admission, except for 19,20-DiHDPA. No PUFAs or oxylipins differentiated patients who developed DCI. We characterized a distinct plasma PUFA- and oxylipin profile in aSAH patients at admission and identified a significant decline in PUFA and oxylipin levels by day 4 post-admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.